Bioabsorbable Magnesium Alloy Coils for Aneurysm Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for intracranial and renal artery aneurysms using non-bioabsorbable metallic coils face challenges such as high recurrence rates, frequent retreatment, and the risk of hemorrhage due to permanent foreign body presence.
Innovation Solution
Development of bioabsorbable metallic alloy coils coated with a fatty amide-based polyurethane urea (PHEUU) elastomer, which acutely occludes aneurysms, initiates tissue generation to fill the aneurysm, and resorbs over time, avoiding long-term foreign body presence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-bioabsorbable metallic coils are used for aneurysm embolization, then acute occlusion is achieved, but recurrence rate increases and foreign body presence persists long-term
Solution Approach 1:
The patent changes the material parameter of the coils from non-bioabsorbable (permanent) to bioabsorbable (temporary), allowing the coils to degrade over time. This resolves the contradiction by maintaining reliable occlusion during the critical healing period while eliminating the harmful foreign body presence long-term through controlled degradation of the magnesium alloy material.
Solution Approach 2:
The patent employs temporary bioabsorbable coils that serve their occlusion function acutely and then degrade completely, replacing the concept of permanent implants with temporary, disposable-like devices that are eliminated by the body after fulfilling their therapeutic purpose.
2Strength
If non-bioabsorbable coils are used, then structural support is maintained, but tissue generation and complete replacement is prevented
Solution Approach 1:
The patent introduces dynamic temporal evolution of the coil material properties - the coils provide strong structural support initially, then gradually degrade over time (6-24 months) as tissue generates and replaces the aneurysm. This dynamic transition from permanent to temporary support resolves the contradiction between maintaining strength and enabling tissue generation.
3Manufacturing precision
If hybrid polymer-coated metallic coils are used, then filling is improved, but long-term foreign body contact delays recovery
Solution Approach 1:
The patent uses composite magnesium alloy coils that combine the benefits of metallic structural support with bioabsorbability, eliminating the need for permanent polymer coatings. The magnesium alloy itself provides the necessary mechanical properties while being temporarily present, improving recovery by removing the long-term foreign body contact issue while maintaining adequate filling quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PHEUU-coated bioabsorbable coils effectively reduce recurrence rates by promoting tissue growth and complete resorption, minimizing the risk of hemorrhage and foreign body-related complications.
Implementation Method 1
The coating protects the magnesium alloy from acute corrosion
Implementation Method 2
The PHEUU coating degrades and is eliminated by the body
Implementation Method 3
The PHEUU coating degrades and is eliminated by the body
Implementation Method 4
magnesium alloy...degrades over a period of time
Implementation Method 5
magnesium alloy...degrades over a period of time
Data Source
AI summary
The invention includes bioabsorbable metallic alloy coils coated with one or more of a biodegradable elastomer, polymer, polyurethane, and/or polyurethane urea, and methods for treating intracranial aneurysms and renal artery aneurysms. According to the invention, a coated, biodegradable vaso-occlusive device includes at least one endovascular coil composed of a magnesium alloy and a coating including at least one of a biodegradable elastomer, polymer, polyurethane, and polyurethane urea, applied to or deposited onto a surface of the magnesium alloy. The vaso-occlusive device is introduced into a patient's body, transported to a targeted site, and implanted at the targeted site to treat the patient having an abnormal blood flow at the targeted site.